INmune Bio prices $4.5M direct offering and concurrent warrant placement

INmune Bio Inc. (NASDAQ: INMB) announced it has entered into a definitive agreement with a single healthcare-focused institutional investor for a registered direct offering of 3,000,000 shares of common stock, along with a concurrent private placement of warrants to purchase up to 3,000,000 additional shares.

The gross proceeds from the combined offering are expected to total approximately $4.50 million, before placement agent fees and other offering expenses. The company said it intends to use the net proceeds for working capital and general corporate purposes.

The warrants carry an exercise price of $1.65 per share, become exercisable six months after issuance, and expire 5.5 years from the issuance date.

The closing is expected to occur on or about October 29, 2026, subject to customary closing conditions. A.G.P./Alliance Global Partners is serving as the sole placement agent for the offering.

The shares are being offered under an existing shelf registration statement on Form S-3, declared effective by the Securities and Exchange Commission on August 7, 2024. The warrants are being issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933. INmune Bio has agreed to file a registration statement covering the resale of shares underlying the warrants within 30 days of closing.

You May Also Be Interested In

• Hydrofarm closes $8.3M offering, eliminates $109M term loan
• Mineralys publishes Phase 2 CKD trial results for lorundrostat
• SELLAS Life Sciences hits 80th event in AML phase 3 trial